Academic Journal
Prolonged Remission Induced by FENofibrate in children with newly diagnosed type 1 diabetes (PRIFEN): protocol of a randomised controlled trial
| العنوان: | Prolonged Remission Induced by FENofibrate in children with newly diagnosed type 1 diabetes (PRIFEN): protocol of a randomised controlled trial |
|---|---|
| المؤلفون: | Groele, Lidia, Dzygało, Katarzyna, Kowalska, Agnieszka, Szypowska, Agnieszka |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2024 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Diabetes and endocrinology |
| الوصف: | Introduction Sphingolipids regulate proinsulin folding, insulin secretion and control beta cells apoptosis. Recent evidence has demonstrated that, among other factors, reduced amounts of sulfatide may be relevant in the development of type 1 diabetes (T1D). Thus, fenofibrate, which activates sulfatide biosynthesis, may prolong remission in subjects with T1D. The aim of the study is to evaluate clinical efficacy of fenofibrate on the maintenance of residual beta-cell function in children with newly diagnosed T1D. Methods and analysis A total of 102 children aged 10–17 years with newly diagnosed T1D will be enrolled in a double-blind, two-centre randomised, non-commercial, placebo-controlled trial. Subjects who will meet all inclusion criteria will be randomly assigned to receive fenofibrate at a dose of 160 mg or an identically appearing placebo, orally, once daily, for 12 months. The primary endpoint will be the area under the curve of the C-peptide level during 2-hour responses to a mixed-meal tolerance test (MMTT). Secondary endpoints include fasting and maximum C-peptide concentration in the MMTT, parameters of diabetes control and glucose fluctuations, daily insulin requirement, inflammation markers, genetic analysis, safety and tolerance of the fenofibrate Ethics and dissemination The study protocol was approved by the Bioethics Committee. The results of this study will be submitted to a peer-reviewed diabetic journal. Abstracts will be submitted to international and national conferences. Trial registration number EnduraCT 2020-003916-28. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://bmjopen.bmj.com/cgi/content/short/14/2/e076882; http://dx.doi.org/10.1136/bmjopen-2023-076882 |
| DOI: | 10.1136/bmjopen-2023-076882 |
| الاتاحة: | http://bmjopen.bmj.com/cgi/content/short/14/2/e076882 https://doi.org/10.1136/bmjopen-2023-076882 |
| Rights: | Copyright (C) 2024, British Medical Journal Publishing Group |
| رقم الانضمام: | edsbas.B873B688 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bmjopen-2023-076882 |
|---|